ArticleBlood advances2025

Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates.

Ana Rita da Fonseca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.